Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Q: When will Elanco (ELAN) present at the J.P. Morgan Healthcare Conference in 2026?

Elanco will present on Tuesday, January 13, 2026 at 3:45 p.m. PST (6:45 p.m. EST).

Q: How can investors listen to Elanco's (ELAN) J.P. Morgan presentation?

A live audio webcast will be available in the Events and Presentations section of Elanco's investor website.

Elanco (NYSE: ELAN) will participate in the 44th Annual J.P.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Elanco (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 p.m. EST).

A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, and a replay will be available for a limited time after the event.

Argus Jan 6 session

+3.25% close to close Open Argus

Details

News Market Reaction – ELAN

On Jan 6, the day this news came out, ELAN closed 3.25% above the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Key Figures

Conference date: January 13, 2026 Presentation time PST: 3:45 p.m. PST Target free cash flow: $1B +5 more

Conference date: January 13, 2026; J.P. Morgan Healthcare Conference appearance
Presentation time PST: 3:45 p.m. PST; Analyst Q&A session timing
Target free cash flow: $1B; Expected from 2026–2028 per Investor Day
Innovation revenue: $1.1B; Forecast innovation revenue in 2026
Canine dermatology market: $1.3B; Estimated U.S. canine dermatology market for Befrena
Befrena dosing interval: 6–8 weeks; Recommended dosing interval for Befrena
Current share price: $23.05; Pre‑news price on analysis date
52-week range: $8.02 – $23.7; 52-week low and high before this news

Historical Context

5 past events · Latest: Dec 31

5 events

Dec 31
USDA product approval

24h Move

-0.6%

USDA approval of Befrena for canine allergic and atopic dermatitis.
Dec 18
FDA conditional ok

24h Move

+0.1%

FDA conditional approval for Credelio Quattro-CA1 to treat screwworm in dogs.
Dec 09
Investor Day targets

24h Move

-5.8%

Three‑year plan with growth, leverage and free cash flow targets to 2028.
Nov 26
Board observer role

24h Move

-0.2%

Elanco executive appointed board observer at Neurizon under license deal.
Nov 21
FDA EUA granted

24h Move

+4.8%

FDA Emergency Use Authorization for Credelio CAT to treat screwworm in cats.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Jargon Translator

conditional approval

Conditional approval is a formal confirmation that a product or plan is permitted to proceed, provided certain specified requirements are met within a designated timeframe. For investors, it signals that approval is nearly complete but depends on the fulfillment of specific conditions, which could influence the final outcome or timeline. This status helps stakeholders assess the likelihood of success while identifying any remaining hurdles.

deferred stock units

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

emergency use authorization

A regulatory emergency use authorization allows a government health agency to temporarily permit the use or sale of a medical product—such as a vaccine, test, or treatment—before full formal approval when there is a public health crisis. For investors, an authorization can rapidly open revenue and market access while carrying higher regulatory and demand risk, like a fast-track pass that speeds a product to customers but may still require further review and can affect a company's valuation and future sales prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/06/2026 - 08:00 AM EST

INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).

A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for a limited time at the conclusion of the event.

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302653013.html

SOURCE Elanco Animal Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Elanco (ELAN) present at the J.P. Morgan Healthcare Conference in 2026?

Elanco will present on Tuesday, January 13, 2026 at 3:45 p.m. PST (6:45 p.m. EST).

Who will represent Elanco (ELAN) at the January 13, 2026 presentation?

Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent Elanco and answer analyst questions.

How can investors listen to Elanco's (ELAN) J.P. Morgan presentation?

A live audio webcast will be available in the Events and Presentations section of Elanco's investor website.

Will there be a replay of Elanco's (ELAN) J.P. Morgan presentation?

Yes. A replay will be available for a limited time at the conclusion of the event on the company's investor website.

Will Elanco (ELAN) provide earnings or guidance during the January 13, 2026 session?

The announcement only notes that executives will respond to analyst questions; it does not disclose earnings or guidance.

Where on Elanco's site will the J.P. Morgan webcast be posted for ELAN investors?

The live audio webcast and limited-time replay will be posted in the Events and Presentations section of Elanco's investor website.

Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference